Glenmark Pharmaceuticals has signed a definitive agreement for the divestiture of a 75% stake in its division, Glenmark Life Sciences (GLS), to Indian company Nirma in a deal valued at Rs56.51bn ($679.85m).
Glenmark Life Sciences focuses on producing active pharmaceutical ingredients (API).
As per the deal, Glenmark Pharma is selling the stake in the life sciences unit for Rs615 for each share.
Following the divestiture, Glenmark Pharma will own a 7.84% stake in GLS.
Glenmark Pharmaceuticals chairman and managing director Glenn Saldanha said: “We are pleased to announce this strategic transaction with Nirma, which marks a significant milestone in shaping an independent growth trajectory for GLS.
“This deal aligns with our strategic intent of moving up the value chain to become an innovative/brand-led organisation, with continuous focus on our core therapeutic areas of dermatology, respiratory and oncology.
“It also presents an opportunity for us to strengthen shareholder value through deleveraging and enhancing our overall return profile.”
The conclusion of the deal is subject to necessary closing conditions and approvals from shareholders and regulators.
Following the deal closing, GLS will work as an independent API company under Nirma.
Furthermore, Nirma will make a compulsory open offer to all GLS public shareholders.
Glenmark Pharma continues to maintain growth across all its crucial markets while focusing on return ratios, eventually generating value for the shareholders of the company.
Kotak Investment Banking served as the exclusive financial adviser for Glenmark Pharma and GLS.
S&R Associates and Trilegal were the legal advisers to Glenmark Pharma and GLS, respectively.
Source: pharmaceutical-technology.com
CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.
DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.
Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.
